Long‐term risks and benefits of oral anticoagulation in atrial fibrillation patients with cancer: A report from the GLORIA‐AF registry

Background Anticoagulation therapy in patients with atrial fibrillation (AF) and concomitant cancer can be challenging due to the significantly increased risk of both embolism and bleeding. Moreover, the benefits and risks of vitamin K antagonists (VKA, eg. warfarin) versus non‐vitamin K antagonist...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical investigation 2025-02, Vol.55 (2), p.e14347-n/a
Hauptverfasser:	Li, Meng, Huang, Bi, Lam, Steven Ho Man, Ishiguchi, Hironori, Liu, Yang, Olshansky, Brian, Huisman, Menno V., Chao, Tze‐Fan, Lip, Gregory Y. H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Aged, 80 and over Anticoagulants Anticoagulants - therapeutic use atrial fibrillation Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Bleeding Cancer cancers Cardiac arrhythmia Cardiovascular disease Cardiovascular diseases Cause of Death Comorbidity Coronary artery disease Embolism Embolism - epidemiology Embolism - etiology Embolism - prevention & control Embolisms Female Fibrillation Heart diseases Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Ischemia Ischemic Attack, Transient - epidemiology Ischemic Attack, Transient - prevention & control major bleeding Male Middle Aged Mortality Neoplasms - complications oral anticoagulants Original Phylloquinone Propensity Score Proportional Hazards Models Prospective Studies Registries Regression analysis Risk Assessment Risk management Statistical analysis Stroke Stroke - epidemiology Stroke - etiology Stroke - prevention & control Subgroups Thromboembolism Thromboembolism - epidemiology Thromboembolism - etiology Thromboembolism - prevention & control Transient ischemic attack Vitamin K Warfarin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!